Astellas, Affinivax form vaccine pact | Chemical & Engineering News
Volume 95 Issue 10 | p. 15 | Concentrates
Issue Date: March 6, 2017

Astellas, Affinivax form vaccine pact

Department: Business
Keywords: infectious disease, Streptococcus pneumoniae, vaccines

Astellas Pharma and Affinivax are joining to develop a vaccine targeting Streptococcus pneumoniae, a bacterium that kills more than 1.6 million people per year, according to the World Health Organization. The partners will use Affinivax’s multiple antigen-presenting system technology, said to enable the binding of protective polysaccharides and proteins in a single vaccine. Japan-based Astellas will pay Affinivax $10 million up front as well as potential milestone payments.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment